Artigo
Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study
Fecha
2017Registro en:
Transplant Infectious Disease. Hoboken, v. 19, n. 4, p. -, 2017.
1398-2273
10.1111/tid.12724
WOS:000407219800024
Autor
Cristelli, Marina P. [UNIFESP]
Cofan, Federico
Tedesco-Silva, Helio [UNIFESP]
Trullas, Joan Carles
Santos, Daniel Wagner C. L. [UNIFESP]
Manzardo, Christian
Aguero, Fernando
Moreno, Asuncion
Oppenheimer, Federico
Diekmann, Fritz
Medina-Pestana, Jose O. [UNIFESP]
Miro, Jose Maria
Institución
Resumen
Background: In the developed world, kidney transplantation (KT) in patients with human immunodeficiency virus (HIV) infection is well established. Developing countries concentrate 90% of the people living with HIV, but their experience is underreported. Regional differences may affect outcomes. Objectives: We compared the 3-year outcomes of patients with HIV infection receiving a KT in two different countries, in terms of incomes and development. Methods: This was an observational, retrospective, double-center study, including all HIV-infected patients >18years old undergoing KT. Results: Between 2005 and 2015, 54 KTs were performed (39 in a Brazilian center, and 15 in a Spanish center). Brazilians had less hepatitis C virus co-infection (5% vs 27%, P=.024). Median cold ischemia time was higher in Brazil (25 vs 18hours, P=.001). Biopsy-proven acute rejection (AR) was higher in Brazil (33% vs 13%, P=.187), as were the number of AR episodes (22 vs 4, P=.063). Patient survival at 3years was 91.3% in Brazil and 100% in Spain P=.663. All three cases of death in Brazil were a result of bacterial infections within the first year post transplant. At 3years, survival free from immunosuppressive changes was lower in Brazil (56% vs 90.9%, P=.036). Raltegravir-based treatment to avoid interaction with calcineurin inhibitor was more prevalent in Spain (80% vs 3% P<.001). HIV infection remained under control in all patients, with undetectable viral load and no opportunistic infections. Conclusion: Important regional differences exist in the demographics and management of immunosuppression and antiretroviral therapy. These details may influence AR and infectious complications. Non-AIDS infections leading to early mortality in Brazil deserve special attention.